<tfoot id="ouu4w"><rt id="ouu4w"></rt></tfoot>
  • 
    
  • <bdo id="ouu4w"></bdo>
        <cite id="ouu4w"><table id="ouu4w"></table></cite>
      • 您當前的位置: 首頁-資訊-詳情

        全球要聞:Nation sees therapeutics success

        2023-01-28 12:10:14來源:云視網
        PharmacistscheckprescriptioninformationatafeverclinicinMinhangdistrictofShanghaionJan8.ThesmallmoleculedrugstotreatCOVID-19hadbeenputintouseincommunityhealthcentersinShanghaitobetterplaytheirrolesin"earlydetection,earlyinterventionandearlydiversion".WANGXIANG/XINHUA

        DomesticallydevelopedCOVID-19drugtherapieslowerriskofhospitalization

        Chinawillcreatebroad-spectrumtreatmentstotacklemutatedstrainsoftheCOVID-19virusanddevelopdrugswithnovelmechanismstofightthepathogen,accordingtoadocumentprovidedtoChinaDaily.


        (相關資料圖)

        AsofJan19,atotalof10domesticallymadeCOVID-19drugshadeitherbeengrantedofficialorconditionalmarketapprovalorwereauthorizedtotreatsymptomsofthepathogen,thedocumentstated.

        ThedocumentwasissuedbythespecializedteamforCOVID-19medicineresearchanddevelopmentundertheJointPreventionandControlMechanismoftheStateCouncil,China"sCabinet.

        Chinaalsohad23drugsonthekeyCOVID-19medicinelistthatwereinactivedevelopmentorundergoingreal-worldevidencestudiesafterreceivingmarketapproval,itsaid.

        "Theteamwillcontinuetofacilitatethedevelopmentofsafeandeffectivetreatmentsthatcancoverthewholecourseofthediseaseandaresuitableforallpopulations,"itadded.

        SincetheCOVID-19pandemicbegan,China"snovelcoronavirusdrugdevelopmentprocesshasfollowedthreebroadtechnicalpaths-stoppingthevirusfromenteringcells,inhibitingviralreplicationinthebodyandregulatingthebody"simmunesystem.

        InDecember2021,Chinagrantedofficialmarketapprovaltoitsfirsthomegrownneutralizingmonoclonalneutralizingantibodycocktails-BRII-196andBRII-198.Itisacombinationtherapyadministeredthroughintravenousinfusionthatcanlowertheriskofhospitalizationanddeathbynearly80percent,accordingtoitsphase-threeclinicaltrialresults.

        Meanwhile,Chinesescientistshavebeendevelopingsmall-moleculeoraltreatmentsforCOVID-19.AbreakthroughcameinJulywhenChinagrantedconditionalauthorizationfortheoralantiviralAzvudinetotreatCOVID-19.ThedrugwasoriginallyusedtotreatHIV.

        Thisyear,Chinawillacceleratethedevelopmentofsmall-moleculeoraldrugs.Inmid-January,theNationalMedicalProductsAdministrationreceivedapplicationsformarketapprovalfornewantiviralsSIM0417andVV116.AnotherantiviralcalledRAY1216hadrecentlyfinishedrecruitingforitslate-stageclinicaltrials.

        BesidesfindingtreatmentsforCOVID-19,Chinesescientistsareresearchingnewdrugstopreventinfectionsorregulatethebody"simmunesystem,withahandfulofcandidatescurrentlyinphasetwoorthreeclinicaltrials.SomenotableexamplesincludethetargetedinhibitordrugTDI01andHY3000peptidenasalspray.

        zhangzhihao@chinadaily.com.cn

        標簽: ThedocumentwasissuedbythespecializedteamforCOVID

        上一篇:
        下一篇: